TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29141713

Group type: EXPERIMENTAL
Intervention: CYD‐TDV group (N = 17,230)
Number of subjects: 25826

Group type: COMPARATOR
Intervention: Control group (N = 8,596)
Number of subjects: 25826

Group type: EXPERIMENTAL
Intervention: CYD‐TDV group
Number of subjects: 25826
Study: 24717791

Group type: EXPERIMENTAL
Intervention: as-needed budesonide/formoterol (160/4.5 micrograms; n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: salbutamol (100 micrograms; n = 31)
Number of subjects: 63
Study: 23580444

Group type: EXPERIMENTAL
Intervention: Home-based exercise training with wireless monitoring (CR, n = 26)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care (UC, n = 29)
Number of subjects: 55
Study: 19995858

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 96

Group type: COMPARATOR
Intervention: No colchicine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Immunosuppressives
Number of subjects: 96
Study: 19049687

Group type: EXPERIMENTAL
Intervention: 6-month psychotherapy intervention (N = 9)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Untreated patients (N = 14)
Number of subjects: 58
Study: 16613260

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus Sanpu Xinnao Xin granule (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus Xiaoyao pill (Group C)
Number of subjects: 90
Study: 12814811

Group type: EXPERIMENTAL
Intervention: ORTHO TRI‐CYCLEN Lo (NGM 180/215/250 microg/EE 25 microg)
Number of subjects: 250

Group type: COMPARATOR
Intervention: ORTHO TRI‐CYCLEN (NGM 180/215/250 microg/EE 35 microg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: ORTHO TRI‐CYCLEN Lo
Number of subjects: 250

Group type: COMPARATOR
Intervention: ORTHO TRI‐CYCLEN
Number of subjects: 250
Study: 10655394

Group type: EXPERIMENTAL
Intervention: FluMist vaccine (cold-adapted H1N1, H3N2, and B influenza viruses)
Number of subjects: 0
Study: 8936754

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 19
Study: 1564689

Group type: EXPERIMENTAL
Intervention: Combination of rinsing with 0.2 percent neutral NaF solution and chewing 2.2 mg NaF tablet
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fluoride tablets (2.2 mg NaF tablet)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Fluoride rinse (0.2 percent neutral NaF solution)
Number of subjects: 640
Study: 4076202

Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nicardipine + Metoprolol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg) during dynamic exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg) during dynamic exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nicardipine + Metoprolol) during dynamic exercise
Number of subjects: 20
Study: 30526273

Group type: COMPARATOR
Intervention: Seated control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% LPA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40% LPA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 60% LPA
Number of subjects: 9
Study: 29611029

Group type: EXPERIMENTAL
Intervention: Proactive rapid genetic counseling and testing (RGCT)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 330
Study: 26683007

Group type: EXPERIMENTAL
Intervention: Cancellous iliac bone graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.5 ml of HA/Col
Number of subjects: 15
Study: 25060156

Group type: EXPERIMENTAL
Intervention: Capsaicin and dihydrocapsaicin combination in 30c potency
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22564839

Group type: EXPERIMENTAL
Intervention: 800 mg ofloxacin daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 1,600 mg ofloxacin daily
Number of subjects: 65
Study: 20575288

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with acupoint-injection of botulinum toxin A (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acupoint-injection of botulinum toxin A (Group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Electroacupuncture (Group C)
Number of subjects: 38
Study: 18092249

Group type: EXPERIMENTAL
Intervention: Rapid vaccination schedule (hepatitis B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Accelerated vaccination schedule (hepatitis B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rapid vaccination schedule (combined hepatitis A/B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Accelerated vaccination schedule (combined hepatitis A/B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rapid vaccination schedule (hepatitis A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Accelerated vaccination schedule (hepatitis A)
Number of subjects: 51
Study: 15590220

Group type: EXPERIMENTAL
Intervention: Activation intervention based on Expanding Patient Involvement in Care (EPIC) trials
Number of subjects: 232

Group type: COMPARATOR
Intervention: Passive education (control) via time-matched viewing of ADA video-tapes
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Activation intervention
Number of subjects: 232
Study: 11902267

Group type: EXPERIMENTAL
Intervention: LPS preincubated with whole blood
Number of subjects: 18

Group type: COMPARATOR
Intervention: LPS preincubated with saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemic blood
Number of subjects: 18
Study: 10502572

Group type: EXPERIMENTAL
Intervention: Suction applied under ophthalmic drapes
Number of subjects: 50

Group type: COMPARATOR
Intervention: No suction used under ophthalmic drapes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (suction and no suction)
Number of subjects: 50
Study: 7751511

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 1661654

Group type: EXPERIMENTAL
Intervention: Fatiguing exercise of the sternomastoid muscle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tetanic stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximal voluntary contraction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (pre-fatigue state)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fatiguing exercise effect on quadriceps twitch maximum relaxation rate
Number of subjects: 10
Study: 7165687

Group type: EXPERIMENTAL
Intervention: Hu IFN‐alpha
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 27
Study: 27240198

Group type: EXPERIMENTAL
Intervention: Iodine group (30 patients); aqueous iodine solution applied intrapleurally.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Doxycycline group (34 patients); 200 mg of Doxycycline given.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Drainage group (35 patients); Lidocaine solution only applied.
Number of subjects: 99
Study: 26817929

Group type: EXPERIMENTAL
Intervention: Relaxation music (standard of care protocol with music)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard of care protocol (control group)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 197
Study: 24395525

Group type: EXPERIMENTAL
Intervention: 30 mg/day vesnarinone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 60 mg/day vesnarinone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 22362012

Group type: EXPERIMENTAL
Intervention: Reflectometry for measuring MPOD in healthy subjects
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reflectometry for measuring MPOD in AMD patients
Number of subjects: 49
Study: 20117269

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPV23)
Number of subjects: 101

Group type: COMPARATOR
Intervention: 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 101
Study: 17388708

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40-120 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15578203

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1) body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12168365

Group type: EXPERIMENTAL
Intervention: Hypothermia (cooled to 34 degrees C within 3 hours after injury, maintained at 32-34 degrees C for 48 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional treatment (without hypothermia)
Number of subjects: 14
Study: 10534584

Group type: EXPERIMENTAL
Intervention: Maprotiline (up to 150 mg daily)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Paroxetine (up to 30 mg daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine hydrochloride up to 37.5 mg daily)
Number of subjects: 103
Study: 7587902

Group type: EXPERIMENTAL
Intervention: Preservation of vagal trunks (PG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine severing of vagal trunks (CG)
Number of subjects: 47
Study: 1969980

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 88
Study: 358738

Group type: EXPERIMENTAL
Intervention: THP-induction test with fibroblast cultures
Number of subjects: 24
Study: 30737046

Group type: EXPERIMENTAL
Intervention: Long-term weekly iron supplementation
Number of subjects: 1286
Study: 30990861

Group type: EXPERIMENTAL
Intervention: BD MAX PCR assay
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: GenomEra PCR assay
Number of subjects: 902

Group type: COMPARATOR
Intervention: Combined reference standard
Number of subjects: 902
Study: 27097790

Group type: EXPERIMENTAL
Intervention: Protocol B (spectral CT imaging with ASIS and 40 to 70 keV monochromatic images, ASIR algorithm)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Protocol A (120 kVp/450 mgI/kg, filtered back projection algorithm)
Number of subjects: 160
Study: 25549765

Group type: EXPERIMENTAL
Intervention: LPS (0.3 ng/kg body weight) injection in trained (T) group
Number of subjects: 17

Group type: COMPARATOR
Intervention: LPS (0.3 ng/kg body weight) injection in untrained (UT) group
Number of subjects: 17
Study: 23169768

Group type: EXPERIMENTAL
Intervention: Surfactant (S) irrigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypertonic saline (HS) irrigation
Number of subjects: 40
Study: 22854544

Group type: EXPERIMENTAL
Intervention: Small group-based CVD prevention education program (8 sessions over 6 weeks and 3 telephone interviews at 2-week intervals)
Number of subjects: 68
Study: 19136337

Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 96
Study: 17420832

Group type: EXPERIMENTAL
Intervention: bromazepam (3mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo 1
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo 2
Number of subjects: 10
Study: 15377055

Group type: EXPERIMENTAL
Intervention: NADH
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nutritional supplements and psychological therapy
Number of subjects: 31
Study: 11806483

Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental fluoride-releasing resin-based composite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional resin-based composite
Number of subjects: 0
Study: 9553912

Group type: EXPERIMENTAL
Intervention: Dithranol ointment treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Before treatment
Number of subjects: 27
Study: 7934767

Group type: EXPERIMENTAL
Intervention: 20 min exercise duration at 70% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 min exercise duration at 70% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 min exercise duration at 70% VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (sitting)
Number of subjects: 8
Study: 3323113

Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/mL
Number of subjects: 200

Group type: COMPARATOR
Intervention: ioxaglate 320 mg I/mL
Number of subjects: 200
Study: 28872898

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST) program - six weekly telephone sessions plus access to a study website
Number of subjects: 175

Group type: COMPARATOR
Intervention: Education program
Number of subjects: 175
Study: 26727409

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 105
Study: 25068511

Group type: EXPERIMENTAL
Intervention: Virtual environment comprising 18 computer games covering mathematics topics
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional teaching methods (Control Group)
Number of subjects: 26
Study: 22420841

Group type: EXPERIMENTAL
Intervention: Azithromycin (one drop twice daily for 3 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tobramycin (1 drop 4 times daily until complete re-epithelialization)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 46
Study: 20450634

Group type: EXPERIMENTAL
Intervention: Computer-driven weaning (CDW) with Smart Care/PS (SC group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physician-directed weaning (PDW) with synchronized intermittent mandatory ventilation plus positive support ventilation (SP group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 18681754

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 15955208

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg)
Number of subjects: 15
Study: 12437706

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 30
Study: 10353376

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal comparison participants
Number of subjects: 22
Study: 8623797

Group type: EXPERIMENTAL
Intervention: Smokers (smoking > or = 16 cigarettes per day)
Number of subjects: 2956

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 2956

Group type: EXPERIMENTAL
Intervention: Smokers (general)
Number of subjects: 2956
Study: 1742504

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6813481

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) 3 mg bid
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 30646500

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including food workshop, five walks, and a smartphone application for three months.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group received brief advice about healthy eating and physical activity.
Number of subjects: 204
Study: 28373643

Group type: EXPERIMENTAL
Intervention: 3D printed skulls
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cadaveric skulls
Number of subjects: 79

Group type: COMPARATOR
Intervention: Atlas
Number of subjects: 79
Study: 26584195

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant interleukin‐1 receptor antagonist)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 763
Study: 24657803

Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standardized sotalol
Number of subjects: 148
Study: 19619297

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study: 17143187

Group type: EXPERIMENTAL
Intervention: Breathing 100% oxygen for 15 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air for 15 min
Number of subjects: 12
Study: 15195012

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Number of subjects: 32

Group type: COMPARATOR
Intervention: 140 ml of contrast material at 4 ml/s
Number of subjects: 32
Study: 11402632

Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg bid (total 4 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: trospium chloride 15 mg tid (total 45 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: oxybutynin 5 mg tid (total 15 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 9737760

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg sustained-release capsule once daily) plus low-dose dexamethasone (4 mg every 12 h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Acetazolamide (500 mg once daily) plus placebo (every 12 h)
Number of subjects: 13
Study: 7977146

Group type: EXPERIMENTAL
Intervention: Milk chocolate bar (46 g)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-carbohydrate snack
Number of subjects: 42
Study: 2593864

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1 mg (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 0.5 mg (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 5 mg (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 2.5 mg (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High progestogen doses (Norethisterone acetate 1 mg and Megestrol acetate 5 mg) with women under 67 kg or last menstruation over 5 years ago
Number of subjects: 60
Study: 30192327

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide plus enhanced recovery after surgery on postoperative day 1 and 2
Number of subjects: 123

Group type: COMPARATOR
Intervention: Enhanced recovery after surgery alone
Number of subjects: 123
Study: 26833820

Group type: EXPERIMENTAL
Intervention: ERSPC-RC
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: ERSPC-PHI
Number of subjects: 2001

Group type: COMPARATOR
Intervention: PCPT-RC
Number of subjects: 2001

Group type: COMPARATOR
Intervention: ERSPC-RC vs PCPT-RC
Number of subjects: 2001

Group type: COMPARATOR
Intervention: ERSPC-RC vs ERSPC-PHI
Number of subjects: 2001
Study: 24513589

Group type: EXPERIMENTAL
Intervention: Implementation of Chronic Care Model (CCM) elements via a specially trained practice nurse
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study: 22122753

Group type: EXPERIMENTAL
Intervention: Brief face‐to‐face health promotion intervention with a 'pledge' using brief negotiation techniques
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard advice‐giving techniques (Control)
Number of subjects: 128
Study: 20795385

Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 45
Study: 19025058

Group type: EXPERIMENTAL
Intervention: Aniracetam (400 mg, 2 x 200 mg/capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of Aniracetam (400 mg)
Number of subjects: 20
Study: 15083988

Group type: EXPERIMENTAL
Intervention: Pharmacist counseling (three levels)
Number of subjects: 0
Study: 11473680

Group type: EXPERIMENTAL
Intervention: Montelukast (active treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study: 10028858

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha (rIFN-alpha) alone (1.5 million units/m2 body surface, 3 times a week for 24 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oral prednisone (2.2 mg/kg/day for 3 weeks, tapered within 1 week) followed by rIFN-alpha (same dose as above)
Number of subjects: 29
Study: 8015423

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (vasoactive drug) administered postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (untreated patients)
Number of subjects: 0
Study: 2778114

Group type: EXPERIMENTAL
Intervention: Topically applied corticosteroid formulations of different potencies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vehicles
Number of subjects: 0
Study: 31573086

Group type: EXPERIMENTAL
Intervention: Extensive intraoperative peritoneal lavage (EIPL)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard treatment (no EIPL)
Number of subjects: 295
Study: 28279542

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg via intravenous piggyback over 15 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25080450

Group type: EXPERIMENTAL
Intervention: Daclatasvir 20 mg
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Daclatasvir 20 mg (Genotype 4)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg (Genotype 4)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo (Genotype 4)
Number of subjects: 395
Study: 23904676

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Servoventilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 30
Study: 21200078

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 216
Study: 19826270

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by hourly urine output
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by intrathoracic blood volume index
Number of subjects: 16
Study: 16477215

Group type: EXPERIMENTAL
Intervention: Voriconazole and caspofungin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lipid formulation of AmB (Control)
Number of subjects: 40